Decentralized study of COVID vaccine antibody response (STOPCoV): results of a participant satisfaction survey

Simple item page

Simple item page

Full item details

creativework.keywords - en

Surveys

Vaccine development

Blood

COVID 19

Antibody response

Booster doses

Pandemics

Virus testing

dc.contributor.author

Ravindran, Rizani

Szadkowski, Leah

Lovblom, Leif Erik

Clarke, Rosemarie

Huang, Qian Wen

Manase, Dorin

Parente, Laura

Walmsley, Sharon

STOPCoV research team

dc.date.accessioned

2024-01-12T19:31:42Z

dc.date.available

2024-01-12T19:31:42Z

dc.date.issued

2023-05-19

dc.description.abstract - en

The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30-50 years of age. In this sub-study we aimed to determine participant satisfaction for the decentralized processes, accessing the study website and collecting and submitting study specimens. The satisfaction survey was based on a Likert scale developed by a team of three investigators. Overall, there were 42 questions for respondents to answer. The invitation to participate with a link to the survey was emailed to 1253 active participants near the mid-way point of the main STOPCoV trial (April 2022). The results were collated and answers were compared between the two age cohorts. Overall, 70% (83% older, 54% younger cohort, no difference by sex) responded to the survey. The overall feedback was positive with over 90% of respondents answering that the website was easy to use. Despite the age gap, both the older cohort and younger cohort reported ease of performing study activities through a personal electronic device. Only 30% of the participants had previously participated in a clinical trial, however over 90% agreed that they would be willing to participate in future clinical research. Some difficulties were noted in refreshing the browser whenever updates to the website were made. The feedback attained will be used to improve current processes and procedures of the STOPCoV trial as well as share learning experiences to inform future fully decentralized research studies.

dc.description.sponsorship

This study was funded in part by the Public Health Agency of Canada through a grant from the Canadian Immunity Task force (CITF ID: 087-VS), the Canadian Institutes of Health Research (EG2-179431), and through a contribution from the Speck family through the University Health Network Foundation (Speck Family COVID-19 Research) to SW as the principal investigator.

dc.identifier.doi

https://doi.org/10.1371/journal.pdig.0000242

dc.identifier.issn

2767-3170

dc.identifier.pubmedID

37159470

dc.identifier.uri

https://open-science.canada.ca/handle/123456789/1764

dc.language.iso

en

dc.publisher

PLOS

dc.rights - en

Creative Commons Attribution 4.0 International (CC BY 4.0)

dc.rights - fr

Creative Commons Attribution 4.0 International (CC BY 4.0)

dc.rights.openaccesslevel - en

Gold

dc.rights.openaccesslevel - fr

Or

dc.rights.uri - en

https://creativecommons.org/licenses/by/4.0/

dc.rights.uri - fr

https://creativecommons.org/licenses/by/4.0/deed.fr

dc.subject - en

Health

dc.subject - fr

Santé

dc.subject.en - en

Health

dc.subject.fr - fr

Santé

dc.title - en

Decentralized study of COVID vaccine antibody response (STOPCoV): results of a participant satisfaction survey

dc.type - en

Article

dc.type - fr

Article

local.acceptedmanuscript.articlenum

e0000242

local.article.journalissue

5

local.article.journaltitle

PLOS Digital Health

local.article.journalvolume

2

local.pagination

1-20

local.peerreview - en

Yes

local.peerreview - fr

Oui

Download(s)

Original bundle

Now showing 1 - 1 of 1

Name: ravindran-decentralized-study-of-covid-vaccine-antibody-response.pdf

Size: 484.78 KB

Format: PDF

Download file